Preclinical Toolbox

Looking to advance your research? Use our optimised compounds to explore and validate mechanisms and pathways in disease-related models of interest to you.


We offer compounds with optimised pharmacological properties for preclinical research that will advance scientific knowledge by exploring novel disease biology. 

Types of preclinical studies considered:

  • In vitro studies that support understanding of disease biology using cells and/or ex vivo tissues from humans or animals
  • In vivo animal studies in models that have translatable endpoints to human disease and could be used to support progression to clinical studies
  • Compound/mechanism combination studies to uncover synergies between pathways leading to novel disease insight and potential therapies.

Let's partner in preclinical research

We invite disease expert physicians and basic scientists to partner with us, with each other and with public or private funding bodies to brainstorm, design and execute preclinical translational research. The aim is to generate high quality, novel data to support the future discovery and development of new therapeutics through target validation, efficacy in models of disease and mechanistic insight into the pathophysiology of human disease.

Interested investigators are invited to:

  • Explore our sortable Preclinical Table of Compounds and examine the key properties of any  compound/mechanism of interest
  • Learn the process, criteria, and rough timelines for proposal submission through to full project plan development and final approval
  • Submit a short 2-3 page ‘Concept Proposal’.

Additional marketed, biologic and late-stage clinical development compounds are offered via the AstraZeneca Externally Sponsored Scientific Research portal.

Submitting a preclinical research proposal



Preclinical compounds available

Filter By

Display
Compound Mechanism of action Originating therapeutic area Proposal type CNS Penetrant Target class Original indication Route
AZ11657312 Mechanism of action Purinergic receptor 2X, ligand-gated ion channel 7 (P2X7) antagonist Originating therapeutic area Inflammation Proposal type Preclinical CNS Penetrant Low Target class Ligand-gated ion channel Original indication COPD, Crohn's, OA, RA Route Oral
AZ12419304 Mechanism of action B-Raf serine/threonine-protein kinase (BRAF) and V600E mutation inhibitor  Originating therapeutic area Oncology Proposal type Preclinical CNS Penetrant Unknown Target class Kinase Original indication Oncology Route Oral
AZ12609721 Mechanism of action Ephrin receptor B4 (EphB4) tyrosine kinase inhibitor  Originating therapeutic area Oncology Proposal type Preclinical CNS Penetrant Unknown Target class Kinase Original indication Oncology Route Oral
AZ12861903 Mechanism of action Growth hormone secretagogue receptor type 1a (GHS-R1a) inverse agonist; ghrelin receptor inverse agonist Originating therapeutic area Metabolic Disease Proposal type Preclinical CNS Penetrant Yes Target class GPCR Original indication Obesity Route Oral
AZ12971554 Mechanism of action Thrombin inhibitor Originating therapeutic area Cardiovascular Proposal type Preclinical CNS Penetrant Unknown Target class Enzyme Original indication Thromboembolism prevention Route Oral
AZ12977847 Mechanism of action Negative allosteric modulator of human mGluR5d, human mGluR5b Originating therapeutic area GI Proposal type Preclinical CNS Penetrant Low Target class GPCR Original indication gastro-oesophageal reflux disease Route Oral
AZ13483342 Mechanism of action Melanin concentrating hormone receptor 1 (MCH1) antagonist  Originating therapeutic area Metabolic Disease Proposal type Preclinical CNS Penetrant Yes Target class GPCR Original indication Obesity Route Oral
AZ13767370 (Compound 13) Mechanism of action Covalent Erk1/2 inhibitor Originating therapeutic area Oncology Proposal type Preclinical CNS Penetrant Unknown Target class Kinase Original indication Oncology Route Oral
AZ13792138 Mechanism of action Inhibitor of the enzyme MTH1 Originating therapeutic area Oncology Proposal type Preclinical CNS Penetrant Unknown Target class Hydrolase Original indication Preclinical Route Oral
AZ20 Mechanism of action ATR serine/threonine kinase inhibitor Originating therapeutic area Oncology Proposal type Preclinical CNS Penetrant Unknown Target class Kinase Original indication Oncology Route Oral
AZ32 Mechanism of action ATM kinase inhibitor Originating therapeutic area Oncology Proposal type Preclinical CNS Penetrant Yes Target class Kinase Original indication ATM kinase inhibitor (for preclinical use to radiosensitise tumour cells in vitro and in vivo) Route Oral
AZ6102 Mechanism of action Tankyrase 1 and 2 inhibitor (TNKS1/2) inhibitor    Originating therapeutic area Oncology Proposal type Preclinical CNS Penetrant Unknown Target class Enzyme Original indication various tumor types Route IV
AZD0328 Mechanism of action Nicotinic acetylcholine receptor alpha 7 (α7 nAChR) agonist Originating therapeutic area CNS Proposal type Clinical & Preclinical CNS Penetrant Yes Target class Ligand-gated ion channel Original indication Cognitive impairment Route Oral
AZD1208 Mechanism of action Proviral integration Moloney virus (PIM) serine/threonine kinase family inhibitor      Originating therapeutic area Oncology Proposal type Preclinical CNS Penetrant Yes Target class Kinase Original indication AML; Advanced Solid Tumours; Malignant Lymphoma Route Oral
AZD1236 Mechanism of action Matrix metalloproteinase 9 & 12 (MMP9,12) inhibitor Originating therapeutic area Inflammation Proposal type Clinical & Preclinical CNS Penetrant Low Target class Enzyme Original indication COPD Route Oral
AZD1332 Mechanism of action Neurotrophic tyrosine kinase receptor (NTRK; or  Tropomycin-related kinase,Trk) inhibitor      Originating therapeutic area Oncology Proposal type Preclinical CNS Penetrant Unknown Target class Kinase Original indication Oncology Route Oral
AZD1656 Mechanism of action Glucokinase (GK; hexokinase 4) activator Originating therapeutic area Metabolic Disease Proposal type Clinical & Preclinical CNS Penetrant Low Target class Enzyme Original indication Diabetes Route Oral
AZD1775 Mechanism of action WEE1 G2 checkpoint kinase inhibitor  Originating therapeutic area Oncology Proposal type Clinical & Preclinical CNS Penetrant Unknown Target class Kinase Original indication Advanced Solid Tumours Route Oral
AZD1981 Mechanism of action Chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTh2) antagonist [prostaglandin D2 (DP2) receptor antagonist] Originating therapeutic area Inflammation Proposal type Clinical & Preclinical CNS Penetrant Low Target class GPCR Original indication Asthma, COPD Route Oral
AZD2014 Mechanism of action Mammalian target of rapamycin (mTOR) serine/threonine kinase (dual TORC1 and TORC2) inhibitor  Originating therapeutic area Oncology Proposal type Clinical & Preclinical CNS Penetrant Unknown Target class Kinase Original indication Solid Tumours Route Oral
AZD2927 Mechanism of action Acetylcholine-regulated inwardly rectifying potassium current (IKACh) blocker  Originating therapeutic area Cardiovascular Proposal type Preclinical CNS Penetrant Low Target class Ligand-gated ion channel Original indication Atrial fibrillation Route IV
AZD3463 Mechanism of action Anaplastic lymphoma tyrosine kinase (ALK) and insulin growth factor1 receptor (IGF1R) tyrosine kinase inhibitor    Originating therapeutic area Oncology Proposal type Preclinical CNS Penetrant Unknown Target class Kinase Original indication Non-Small Cell Lung Cancer (NSCLC) Route Oral
AZD3759 Mechanism of action Epidermal growth factor receptor (EGFR) tyrosine kinase sensitising mutations inhibitor  Originating therapeutic area Oncology Proposal type Preclinical CNS Penetrant Yes Target class Kinase Original indication Non-small cell lung cancer (NSCLC) Route Oral
AZD3857 Mechanism of action Melanin concentrating hormone receptor 1 (MCH1) antagonist and acetylcholinesterase (AChE) inhibitor    Originating therapeutic area Metabolic Disease Proposal type Preclinical CNS Penetrant Yes Target class GPCR Original indication Obesity Route Oral
AZD4017 Mechanism of action 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor Originating therapeutic area Metabolic Disease Proposal type Clinical & Preclinical CNS Penetrant Low Target class Enzyme Original indication Diabetes Route Oral
AZD4547 Mechanism of action Fibroblast growth factor receptor (FGFR) tyrosine kinase family inhibitor      Originating therapeutic area Oncology Proposal type Preclinical CNS Penetrant Low Target class Kinase Original indication Solid Tumours Route Oral
AZD4877 Mechanism of action Kinesin spindle protein (KSP; also called Eg5) inhibitor  Originating therapeutic area Oncology Proposal type Preclinical CNS Penetrant Low Target class Enzyme Original indication Haematopoietic and Solid Malignancies Route IV
AZD5069 Mechanism of action Chemokine (C-X-C motif) receptor 2 (CXCR2) antagonist Originating therapeutic area Inflammation Proposal type Clinical & Preclinical CNS Penetrant Unknown Target class GPCR Original indication Asthma Route Oral
AZD5213 Mechanism of action Histamine receptor 3 (H3) antagonist (inverse agonist) Originating therapeutic area CNS Proposal type Clinical & Preclinical CNS Penetrant Yes Target class GPCR Original indication Cognition, Daytime Sleepiness, Tourette's Route Oral
AZD5363 Mechanism of action AKT serine/threonine protein kinase (also known as protein kinase B alpha) inhibitor  Originating therapeutic area Oncology Proposal type Preclinical CNS Penetrant Low Target class Kinase Original indication Solid & Haematological Malignancies Route Oral
AZD5582 Mechanism of action Second mitochondria-derived activator of caspase (Smac) mimetic [inhibitor of apoptosis protein (IAP) antagonist]  Originating therapeutic area Oncology Proposal type Preclinical CNS Penetrant Unknown Target class Apoptotic Original indication Solid Tumours Route IV
AZD5904 Mechanism of action Myeloperoxidase (MPO) inhibitor Originating therapeutic area Inflammation Proposal type Clinical & Preclinical CNS Penetrant Low Target class Enzyme Original indication COPD, MS Route Oral
AZD6495 Mechanism of action Colony stimulating factor-1 receptor (CSF-1R) tyrosine kinase inhibitor  Originating therapeutic area Oncology Proposal type Preclinical CNS Penetrant Unknown Target class Kinase Original indication Oncology Route Oral
AZD6738 Mechanism of action Ataxia Telangiectasia and Rad3 related (ATR) serine/threonine protein kinase inhibitor  Originating therapeutic area Oncology Proposal type Preclinical CNS Penetrant Unknown Target class Kinase Original indication Chronic Lymphocytic Leukaemia (CLL) Route Oral
AZD7325 Mechanism of action Gamma-aminobutyric acid receptor A alpha 2 & 3 (GABAAα2,3) positive modulator    Originating therapeutic area CNS Proposal type Clinical & Preclinical CNS Penetrant Yes Target class Ligand-gated ion channel Original indication General Anxiety Disorder Route Oral
AZD7762 Mechanism of action Checkpoint kinase 1 and 2 (Chk1/2) inhibitor   Originating therapeutic area Oncology Proposal type Preclinical CNS Penetrant Low Target class Kinase Original indication Solid and Haematological Tumours Route IV
AZD8186 Mechanism of action Phosphatidylinositol-4, 5-bisphosphate 3-kinase, catalytic subunit beta (PIK3CB; PI3Kb) and delta (PIK3CD; PI3Kd) inhibitor    Originating therapeutic area Oncology Proposal type Preclinical CNS Penetrant Unknown Target class Kinase Original indication Solid Tumours Route Oral
AZD8329 Mechanism of action 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor Originating therapeutic area CVMD Proposal type Preclinical CNS Penetrant Low Target class Enzyme Original indication Diabetes Route Oral
AZD8529 Mechanism of action Metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulator Originating therapeutic area CNS Proposal type Preclinical CNS Penetrant Yes Target class GPCR Original indication Schizophrenia Route Oral
AZD8542 Mechanism of action Smoothened (SMO), frizzled family receptor antagonist  Originating therapeutic area Oncology Proposal type Preclinical CNS Penetrant Unknown Target class GPCR Original indication Oncology Route Oral
AZD8835 Mechanism of action Class I PI3K isoforms, PI3Kinase α and PI3Kinase δ Originating therapeutic area Oncology Proposal type Preclinical CNS Penetrant Unknown Target class Kinase Original indication ER+ve breast cancer Route Oral
AZD8931 Mechanism of action Epidermal growth factor receptor (EGFR) family (pan-erbB) tyrosine kinase inhibitor      Originating therapeutic area Oncology Proposal type Preclinical CNS Penetrant Low Target class Kinase Original indication Solid Tumours Route Oral
AZD9150 Mechanism of action Signal transducer and activator of transcription 3 (STAT3) antisense  Originating therapeutic area Oncology Proposal type Clinical & Preclinical CNS Penetrant Low Target class Antisense Original indication Hepatocellular Carcinoma Route IV
AZD9668 Mechanism of action Neutrophil elastase (NE) inhibitor  Originating therapeutic area Inflammation Proposal type Clinical & Preclinical CNS Penetrant Low Target class Enzyme Original indication COPD, Cystic Fibrosis Route Oral
Barasertib (AZD1152) Mechanism of action Aurora B serine/threonine kinase inhibitor  Originating therapeutic area Oncology Proposal type Preclinical CNS Penetrant Low Target class Kinase Original indication Acute Myeloid Leukaemia (AML) Route IV
Lesogaberan (AZD3355) Mechanism of action Gamma-aminobutyric acid receptor B (GABAB) agonist   Originating therapeutic area GI Proposal type Clinical & Preclinical CNS Penetrant Low Target class GPCR Original indication GERD Route Oral
Saracatinib (AZD0530) Mechanism of action Src tyrosine kinase family inhibitor Originating therapeutic area Oncology Proposal type Clinical & Preclinical CNS Penetrant Yes Target class Kinase Original indication Oncology Route Oral
Zibotentan (ZD4054) Mechanism of action Endothelin receptor A (ETA) antagonist  Originating therapeutic area Oncology Proposal type Clinical & Preclinical CNS Penetrant Low Target class GPCR Original indication Castration-Resistant Prostate Cancer (CRPC) Route Oral


Useful information

How do I know that the information I submit to AstraZeneca will remain confidential?

AstraZeneca is committed to the same ethical policy that is practiced during grant and manuscript peer-reviews.  That means we will not use or disclose the information submitted, unless approved in writing by the submitter; or the information becomes public, is separately received or independently developed.

What are the typical agreement terms?

The AstraZeneca Open Innovation program seeks to utilize terms that facilitate participation, open collaborative brainstorming, problem solving and are consistent with well-established and tested academic-industry agreement structures (e.g., Lambert/miCRA templates in U.K. and NIH/NCATS CRA in U.S.), for example:

  • Pre-existing IP remains with the original owner
  • New IP follows ownership framework taking into account the contribution of each party and where possible using the well-established academic-industry templates
  • Publications are encouraged after allowing AstraZeneca to comment, patent(s) to be filed (if applicable), AstraZeneca confidential information protected
  • If the collaboration generates positive findings, AstraZeneca has option to negotiate a license to advance further towards patient benefit and commercialization
  • For compounds ‘live’ in development, AstraZeneca minimally receives non-exclusive, royalty-free, fully paid license, with the right to sublicense without limitation, for all purposes for project IP

Ownership of project IP is based on multiple factors including regional/country standards, IP policies and the current development stage/status of the compound